Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
1998

Infusional CMF in Metastatic Breast Cancer

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): KJ O'Byrne, ML Koukourakis, MP Saunders, AJ Salisbury, R Isaacs, S Varcoe, M Taylor, TS Ganesan, AL Harris, DC Talbot

Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, The Churchill, Oxford Radcliffe Hospital, Oxford, UK

Hypothesis

The study aimed to evaluate the efficacy and tolerability of a modified 'classical' CMF regimen replacing bolus 5-FU with continuous infusional 5-FU.

Conclusion

Infusional 5-FU can be administered safely and is effective in combination with cyclophosphamide and methotrexate in the treatment of metastatic breast cancer.

Supporting Evidence

  • Objective tumour responses were seen in 9 of 25 patients (36%).
  • The median overall survival was 10 months.
  • Infusional 5-FU was well tolerated with manageable side effects.
  • Grade III/IV neutropenia was a significant toxicity observed in some cohorts.
  • Responses were seen in all four cohorts of the study.

Takeaway

This study tested a new way to give chemotherapy for breast cancer, and it worked well for many patients.

Methodology

A phase I/II dose-finding study evaluating the combination of infusional 5-FU with cyclophosphamide and methotrexate in 25 patients with metastatic breast cancer.

Potential Biases

Potential bias due to lack of randomization and the open-label design.

Limitations

The study had a small sample size and was not randomized.

Participant Demographics

Median age of participants was 51 years, with a range from 33 to 69 years, all women with stage IV breast cancer.

Statistical Information

Confidence Interval

95% CI 18-58%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication